openPR Logo
Press release

The Vascular Endothelial Growth Factor market is segmented according to the mode of action of the drug, route of administration, end users, and geography.

10-31-2018 07:53 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Future Market Insights

The Vascular Endothelial Growth Factor market is segmented

Vascular Endothelial Growth Factor (VEGF), is a process of formation of new blood vessels from endothelial cells or the pre-existing vessels. VEGF’s normal function is during embryonic development, the formation of new blood vessels after injury, in muscle after exercise and as a bypass for a blocked vessel. Overexpression of VEGF can be fatal as they can grow into cancerous cells. VEGF plays both beneficial and damaging roles in organisms. VEGF takes circulating endothelial precursor cells and acts as a growth medium for immature tumor cells. The affinity of VEGF toward endothelial cells is mediated through VEGF-specific tyrosine-kinase receptor: VEGFR-1, VEGFR-2, and VEGFR-3. Hence VEGF and its receptors play a major role in the growth of tumor cells. The endotheliotropic property of VEGF causes a major concern for developing Vascular Endothelial Growth Factor Receptor Inhibitor. The VEGF family in mammals comprises of members VEGF-A, VEGF-B, VEGF-C, VEGF-D, and PIGF, out of these the VEGF-A is responsible for angiogenesis and migration and mitosis of endothelial cells. Many therapeutic strategies are developed for inhibiting the signal transduction of VEGF. Some of the therapeutic options are monoclonal antibodies against VEGF or VEGFR, soluble VEGF and VEGFR hybrids and tyrosine kinase inhibitors.

Vascular Endothelial Growth Factor Inhibitor Market: Drivers and Restraints

The global increase in the prevalence of cancer and recognition of therapeutic opportunities offered by oncology treatments have boosted pharmaceutical industry to develop new agents to treat cancer. According to WHO, the new cancer cases are expected to rise by 70% in coming two decades. Approximately 60% of malignant tumors express high concentrations of VEGF, therapeutic option to inhibit the VEGF tumor causing pathway has become a major concern for all researchers.

Request Sample Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-3292

Some of the restraining factors for VEGF inhibitor to be a silver bullet in the treatment of cancer is that angiogenesis is not the only factor causing a tumor. While the lesser known restraints are the side effects caused by VEGF inhibitors are bleeding and increased blood pressure

Vascular Endothelial Growth Factor Inhibitor Market: Segmentation

The Vascular Endothelial Growth Factor market is segmented according to the mode of action of the drug, route of administration, end users, and geography. The segmentation by mode of action of the drug is tyrosine kinase inhibitor: inhibits the adenosine triphosphate binding site, monoclonal antibody: they bind to VEGF-A preventing it from binding to receptors and activating the signaling cascades that lead to angiogenesis and vascular endothelial growth factor receptor hybrids: act as a decoy receptor and prevents binding of the ligand to its natural receptors. By route of administration, it is segmented as oral and intravenous. By end user, the segmentation is classified as hospitals, ambulatory surgical centers, and cancer research institutes. Segmentation by Geography is North America, West Europe, APEJ, Japan, Eastern Europe, Latin America and the Middle East and Africa.

Vascular Endothelial Growth Factor Inhibitor Market: Overview

Vascular Endothelial Growth Factor Inhibitors are also termed as Angiogenesis Inhibitor which inhibits the growth of the new blood vessels. Angiogenesis Inhibitors are effective in the treatment of cancer macular degeneration in the eye and diseases that involve proliferation of blood vessels. VEGF or angiogenesis is regulated by the activity of endogenous stimulators and inhibitors. Endogenous inhibitors are present in the body involved in regulating the process of blood vessel formation. Endogenous inhibitors are derived from the cellular matrix and basement protein. Among the factors responsible for angiogenesis, VEGF is the most potent and has high expression in ovarian, endometrial and cervical cancer. Inhibition of angiogenesis by VEGF requires anti – VEGF / anti – angiogenesis factors which reduce the production of pro – angiogenic factor thereby preventing them from binding to their receptors. The commonly used therapy for VEGF pathway inhibition is a monoclonal antibody against VEGF or VEGFR, soluble VEGFR hybrids, and tyrosine kinase inhibitors. Among this, the most widely used treatment is with monoclonal antibody Bevacizumab.

Vascular Endothelial Growth Factor Inhibitor Market: Regional Overview

The monoclonal antibody segment is growing faster in North America and Europe vascular endothelial growth factor inhibitor marketvascular endothelial growth factor inhibitor market. North America region accounts for the largest market share for tyrosine kinase inhibitor followed by Asia-Pacific and Europe. China will drive the Asia Pacific market by providing growth opportunities from upcoming companies. In the Asia-Pacific market, the countries like China, India and South Asian countries will dominate the market. According to WHO the emerging market for cancer is Africa, Asia, and the US.

Request to View TOC@ https://www.futuremarketinsights.com/toc/rep-gb-3292

Vascular Endothelial Growth Factor Inhibitor Market: Key Players

Some of the players in the market of Vascular Endothelial Growth Factor Inhibitor are Pfizer Inc., Novartis Pharmaceutical Corporation, AstraZeneca, Bayer Healthcare, Merck & Co. Inc., Genetech Inc., Eli Lilly, Sanofi Aventis, GlaxoSmithKline, Bristol-Myer Squibb and Boehringer Ingelheim

Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centres in the U.S. and India.

FMI’s research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity. Our customised and syndicated market research reports deliver actionable insights that drive sustainable growth. We continuously track emerging trends and events in a broad range of end industries to ensure our clients prepare for the evolving needs of their consumers.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States

T: +1-347-918-3531
F: +1-845-579-5705

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release The Vascular Endothelial Growth Factor market is segmented according to the mode of action of the drug, route of administration, end users, and geography. here

News-ID: 1341111 • Views:

More Releases from Future Market Insights

Medical Implants Precision Machining Service Market Poised for 6.4% CAGR Growth to 2035
Medical Implants Precision Machining Service Market Poised for 6.4% CAGR Growth …
Global Market Outlook: A Decade of Expanding Precision The medical implants precision machining service market is entering a decisive decade, with a strong growth trajectory driven by demand for advanced surgical solutions and innovations in multi-axis machining technologies. According to new projections, the market will expand from USD 1,056.4 million in 2025 to USD 1,964.5 million by 2035, marking a compound annual growth rate (CAGR) of 6.4%. Between 2021 and 2025, the
NGS Solution for Early Cancer Screening Market to Reach USD 2,393.5 million by 2035 Amid Precision Medicine Growth
NGS Solution for Early Cancer Screening Market to Reach USD 2,393.5 million by 2 …
Early Cancer Detection Enters a Transformative Era The fight against cancer is undergoing a profound transformation as the global healthcare sector accelerates the adoption of next-generation sequencing (NGS) technologies for early cancer detection. According to market forecasts, the NGS solution for early cancer screening market will grow from USD 591.6 million in 2025 to nearly USD 2,393.5 million by 2035, representing a 305% total growth and a 15% compound annual growth
Non-Invasive Blood Pressure Analyzer Market to Reach USD 230.7 million by 2035
Non-Invasive Blood Pressure Analyzer Market to Reach USD 230.7 million by 2035
Rising Demand for Non-Invasive Blood Pressure Analyzers The global healthcare and biomedical research landscape is undergoing rapid transformation, with technological innovation and patient-centered solutions shaping its trajectory. One of the most significant markets poised for expansion is the non-invasive blood pressure (NIBP) analyzer sector. According to market forecasts, the NIBP analyzer market will grow from USD 122.9 million in 2025 to USD 230.7 million by 2035, achieving a steady compound annual
Pre-Workout Supplements Market Anticipated to Expand at 7.5% CAGR Through 2035 Amid Rising Health & Wellness Awareness
Pre-Workout Supplements Market Anticipated to Expand at 7.5% CAGR Through 2035 A …
A new market analysis reveals the global pre-workout supplements market is poised for explosive growth, with its value projected to more than double from an estimated USD 21.7 billion in 2025 to a staggering USD 44.7 billion by 2035. This impressive forecast, reflecting a robust Compound Annual Growth Rate (CAGR) of 7.5%, is driven by a confluence of factors, including heightened health awareness, the increasing popularity of high-intensity fitness regimes,

All 5 Releases


More Releases for VEGF

Anti-VEGF Therapeutic Market New Product Development & Latest Trends
The global Anti-VEGF therapeutic market is projected to reach approximately $32.1 billion in 2024, driven by increasing incidences of ocular diseases such as age-related macular degeneration and diabetic retinopathy. Over the forecast period from 2025 to 2034, the market is expected to grow at a compound annual growth rate (CAGR) of around 6.2%, reaching an estimated value of $57.4 billion by 2034. Exactitude Consultancy., Ltd. released a research report offers a
The Increasing Prevalence Of Cancer And Macular Degeneration Diseases Drives The …
The Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Expected Vascular Endothelial Growth Factor (VEGF) Inhibitor Market Size During the Forecast Period? The market size for the inhibitor of vascular endothelial growth factor (VEGF) has seen substantial
VEGF Inhibitor Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2 …
Market Overview and Report Coverage VEGF inhibitor drugs are targeted therapies that block vascular endothelial growth factor (VEGF), a signaling protein that promotes blood vessel formation (angiogenesis) within tumors. By inhibiting VEGF, these drugs can effectively disrupt the supply of nutrients and oxygen to tumors, thereby inhibiting their growth and proliferation. These drugs are primarily used in the treatment of various cancers, including colorectal, renal cell, and lung cancer. The VEGF inhibitor
Anti-VEGF Therapeutics Market In-Deep Research and Forecast Report
The revenue of the anti-VEGF therapeutics market will increase from $12,178.0 million in 2021 at a compound annual growth rate of 1.4% from 2021 to 2030, to touch $13,812.6 million by 2030. The development of the industry is mainly driven by the approvals of the FDA to a number of drug candidates, accompanied by R&D activities. Get the sample pages of this report at: https://www.psmarketresearch.com/market-analysis/anti-vascular-endothelial-growth-factor-therapeutics-market/report-sample Eylea held the largest share in the
Global VEGF/VEGFR Inhibitor Drugs Industry Research Analysis by 2020- 2025
This report also researches and evaluates the impact of Covid-19 outbreak on the VEGF/VEGFR Inhibitor Drugs industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on VEGF/VEGFR Inhibitor Drugs and market growth forecast based on different scenario (optimistic, pessimistic, very optimistic, most likely etc.). GLOBAL INFO RESEARCH has lately published a new report titled, *Global and Japan VEGF/VEGFR Inhibitor Drugs Market 2020 by Company, Type and Application, Forecast to
Vascular Endothelial Growth Factor (VEGF) Inhibitors Market: Competitive Dynamic …
LP INFORMATION offers a latest published report on Vascular Endothelial Growth Factor (VEGF) Inhibitors Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. According to this study, over the next five years the Vascular Endothelial Growth Factor (VEGF) Inhibitors market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024,